Bausch + Lomb (NYSE:BLCO) PT Lowered to $15.00 at Evercore

Bausch + Lomb (NYSE:BLCO) had its price objective dropped by equities research analysts at Evercore from $17.00 to $15.00 in a research report issued to clients and investors on Thursday, BayStreet.CA reports. The firm presently has an “in-line” rating on the stock. Evercore’s price target would indicate a potential upside of 9.41% from the company’s current price.

A number of other research firms also recently issued reports on BLCO. Evercore ISI boosted their price target on shares of Bausch + Lomb from $16.50 to $17.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Royal Bank of Canada decreased their price target on Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, April 22nd. Wells Fargo & Company lifted their price objective on Bausch + Lomb from $21.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, February 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Bausch + Lomb in a report on Thursday. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and an average price target of $19.27.

Bausch + Lomb Trading Down 0.2 %

BLCO stock traded down $0.03 during midday trading on Thursday, hitting $13.71. 704,041 shares of the company’s stock were exchanged, compared to its average volume of 484,706. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.95. The company has a current ratio of 1.74, a quick ratio of 1.09 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $4.82 billion, a PE ratio of -18.58, a P/E/G ratio of 1.40 and a beta of 0.47. The business has a 50-day simple moving average of $15.97 and a two-hundred day simple moving average of $15.65.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Bausch + Lomb had a positive return on equity of 3.70% and a negative net margin of 6.27%. The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts predict that Bausch + Lomb will post 0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Capital LLC increased its stake in shares of Bausch + Lomb by 3.0% during the first quarter. Renaissance Capital LLC now owns 23,076 shares of the company’s stock worth $399,000 after buying an additional 669 shares during the period. Gabelli Funds LLC increased its position in shares of Bausch + Lomb by 2.3% in the 3rd quarter. Gabelli Funds LLC now owns 263,744 shares of the company’s stock valued at $4,470,000 after purchasing an additional 6,017 shares during the last quarter. Black Swift Group LLC acquired a new stake in shares of Bausch + Lomb in the 3rd quarter valued at $170,000. Brandes Investment Partners LP lifted its position in shares of Bausch + Lomb by 11.0% during the 4th quarter. Brandes Investment Partners LP now owns 114,200 shares of the company’s stock worth $1,948,000 after purchasing an additional 11,321 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Bausch + Lomb during the third quarter worth $255,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.